Premium
CELLULAR PHARMACOLOGY AND OPTIMAL THERAPEUTIC CONCENTRATIONS OF 1‐β‐D‐ARABINOFURANOSYLCYTOSINE 5‘‐TRIPHOSPHATE IN LEUKEMIC BLASTS DURING TREATMENT OF REFRACTORY LEUKEMIA WITH HIGH‐DOSE 1‐β‐D‐ARABINOFURANOSYLCYTOSINE
Author(s) -
Plunkett William,
Iacoboni Stephen,
Keating Michael J.
Publication year - 1986
Publication title -
scandinavian journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0036-553X
DOI - 10.1111/j.1600-0609.1986.tb01590.x
Subject(s) - refractory (planetary science) , cytarabine , leukemia , medicine , pharmacology , continuous infusion , gastroenterology , chemistry , biology , astrobiology
The pharmacology of 1‐β‐D‐arabinofuranosylcytosine 5′‐triphosphate (ara‐CTP) has been studied in the circulating leukemic blasts of patients with refractory leukemia during therapy with high doses of single‐agent ara‐C. Cellular ara‐CTP was analyzed by high‐pressure liquid chromatography. The median trough concentrations of ara‐CTP in blasts of patients who responded to intermittent high‐dose ara‐C (3 g/m 2 × 4–12 doses) was 196 μM, whereas 75 μM was the lowest trough ara‐CTP concentration that discriminated between complete remission and treatment failure (p=0.03). The median steady state ara‐CTP concentrations in the blasts of patients who responded to a high dose continuous infusion protocol (2 doses of 3 g/m 2 every 12 hr followed by a continuous infusion of 330–3000 mg/m 2 × 4 d) were clustered between 79 and 206 μM. The values of treatment failures were predominantly outside this range (p<0.005). These results suggest that the optimal concentration range for intracellular ara‐CTP in the treatment of refractory leukemia may be 75 to 200 μM.